Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | SDCBP | O00560 | 3/20 | 0.39 |
| ▸ | SDC2 | P34741 | 3/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743929 | 0.91 | FOLH1 (0.43) | MMEFOLH1KMT2AATMNAALAD2 | |
| SCHEMBL5743934 | 0.91 | FOLH1 (0.43) | MMEFOLH1KMT2AATMNAALAD2 | |
| SCHEMBL5743248 | 0.89 | MME (0.44) | MMEFOLH1KMT2AATMADAMTS4 | |
| SCHEMBL5742216 | 0.89 | MME (0.56) | MMEKMT2AALDH1A1POLBHTRA1 | |
| SCHEMBL5743794 | 0.86 | FOLH1 (0.46) | MMEFOLH1KMT2AATMALDH1A1 | |
| SCHEMBL4812470 | 0.81 | FOLH1 (0.47) | MMEFOLH1KMT2AATMPOLB | |
| SCHEMBL4808133 | 0.81 | FOLH1 (0.54) | MMEFOLH1KMT2AATMALDH1A1 | |
| SCHEMBL5743939 | 0.80 | FOLH1 (0.43) | MMEFOLH1KMT2AATMADAMTS4 | |
| SCHEMBL5743471 | 0.80 | MME (0.50) | MMEKMT2APOLBHTRA1 | |
| SCHEMBL5743468 | 0.80 | MME (0.50) | MMEKMT2APOLBHTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | claimed |
| EP-1427423-B1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | claimed |
| US-7132416-B2 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | claimed |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | ALBIREO AB (SE) | 2005-02-17 | — | — | US | claimed |
| EP-1427423-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | claimed |
| WO-2003022286-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | claimed |
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-1427423-B1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-7132416-B2 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | ALBIREO AB (SE) | 2005-02-17 | — | — | US | disclosed |
| EP-1427423-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022286-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | SLC10A2, SLC10A1, ABCB11 | MME 1556/4885FOLH1 2382/4885KMT2A 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.